Skip to main content
. 2021 Feb 22;26(4):277–280. doi: 10.1002/onco.13705

Figure 1.

Figure 1

Considerations for choosing FOLFOXIRI + bevacizumab versus FOLFOX + anti‐EGFR therapy for left‐sided RAS/BRAF wild‐type mCRC. Abbreviations: EGFR, epidermal growth factor receptor; FOLFOX, fluorouracil, leucovorin, and oxaliplatin; FOLFOXIRI, fluorouracil, leucovorin, oxaliplatin, and irinotecan; mCRC, metastatic colorectal cancer; ORR, overall response rate; OS, overall survival; PFS, progression‐free survival.